December 14, 2021
Daiichi Sankyo said on December 11 that its EZH1/2 dual inhibitor valemetostat met the primary goal in a Japanese PII study for the treatment of relapsed/refractory adult T-cell leukemia-lymphoma (ATL). The drug, also known as DS-3201, delivered an objective response...read more